Brian Scorney
Biotech analyst / Biotech Hangout panelist · Biotech Hangout panelist
aka Brian Skorney
“It's really hard to think that the FDA could give Amandas and Viondas full approval Based on the Essence Phase 3 data set and not very, very clearly approve Dyn zeros for dmd, given that on pretty much every metric it's better than a Teplerson... I think it's going to get approved.”
“I cover close to 30 names, you know, supporting people on anot”
Brian Scorney
One-line summary: Biotech Hangout panelist; reads FDA rare-disease approval odds through the post-Sarepta regulatory-flexibility lens.
What they're known for
Brief factual context — fill in.
Why they matter to stock-market
Why this person's claims are tracked here — fill in.
Said
Speaker-attributed claims extracted from diarized sources. Each bullet mirrors one entry in quotes: frontmatter — keep them in sync.
-
On fda-right-shift-to-rare-disease-refile-rerate, fda-rare-disease-regulatory-right-shift:
"It's really hard to think that the FDA could give Amandas and Viondas full approval Based on the Essence Phase 3 data set and not very, very clearly approve Dyn zeros for dmd, given that on pretty much every metric it's better than a Teplerson... I think it's going to get approved." — 2026-07-24-podcast-biotech-hangout-episode-190-july-24-2026 (2026-07-24)
-
On fda-right-shift-to-rare-disease-refile-rerate:
"I cover close to 30 names, you know, supporting people on anot" — 2026-08-15-biotech-hangout-episode-192-august-7-2026 (2026-08-07)
Sources
- 2026-07-24-podcast-biotech-hangout-episode-190-july-24-2026
- 2026-08-15-biotech-hangout-episode-192-august-7-2026
Related
Cross-links — fill in.